{"id":"W2954341438","doi":"10.1007/s40259-019-00361-6","title":"Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis","year":2019,"lang":"en","type":"review","venue":"BioDrugs","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":43,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University","funders":"","keywords":"Psoriatic arthritis; Medicine; Psoriasis; Ankylosing spondylitis; Tolerability; Interleukin 17; Immunology; Disease; Interleukin 23; Interleukin 22; Clinical trial; Psoriasis Area and Severity Index; Spondylitis; Interleukin; Dermatology; Internal medicine; Cytokine; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002107591,0.0004510217,0.001253092,0.0001182247,0.0002058132,0.00002245598,0.0001805655,0.0002765025,0.00005371866],"category_scores_gemma":[0.0000498751,0.0002216179,0.0004928327,0.0001249668,0.0003937945,0.00003906135,0.0000767556,0.00008088016,0.00001803585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006969886,"about_ca_system_score_gemma":0.0001446353,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008755975,"about_ca_topic_score_gemma":0.00002592907,"domain_scores_codex":[0.9984419,0.0002144344,0.0006151392,0.0004064819,0.00004579782,0.000276218],"domain_scores_gemma":[0.9973834,0.001510275,0.0005021715,0.0005261723,0.00004611121,0.00003194219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000378549,0.0002301894,0.00009496553,0.004344025,0.002001854,0.000003214579,0.000843376,4.432663e-8,0.00002975906,0.0002230397,0.0005401447,0.9913108],"study_design_scores_gemma":[0.001691293,0.000655104,0.0002430112,0.002033919,0.006708418,0.00003623845,0.0001241937,0.000001035936,0.000238847,0.00002710742,0.9880186,0.0002222561],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01443989,0.9755358,0.000002884281,0.0001253839,0.0009947588,0.001945595,0.006924829,0.00001438112,0.00001645456],"genre_scores_gemma":[0.003976788,0.9940702,0.00002312804,0.00001334237,0.0001561245,0.0003091307,0.0006131505,0.00003559155,0.0008024979],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9910886,"threshold_uncertainty_score":0.9037316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04080093537706545,"score_gpt":0.2807410066708714,"score_spread":0.239940071293806,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}